SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing massive trading volume and a significant surge as investors react to a de-risking FDA update for its ANKTIVA bladder cancer application, which importantly does not require new clinical trials. This news, coupled with recent international approvals and high short interest, has ignited widespread community discussion about a potential short and gamma squeeze. The intense momentum highlights a fervent belief in the drug's long-term potential as a cancer treatment, driving bullish sentiment against a backdrop of active short positions.

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata Inc. is currently trending due to its recent award of a prime contract position on the U.S. Missile Defense Agency's SHIELD program, significantly bolstering its standing in government AI data training. The community is highly bullish on this development, anticipating a major breakout, potential short squeeze, and further expansion into defense and sovereign AI markets, with many viewing the company as undervalued.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to compelling positive Phase 1 data for its oral drug soquelitinib in atopic dermatitis, showcasing strong efficacy in treatment-resistant patients and a favorable safety profile. The community is buzzing about its "best-in-class" potential in a massive market and a possible short squeeze, with many anticipating significant upside or a partnership. Despite the early stage of development, the innovative mechanism is driving substantial investor conversation.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a significant licensing agreement with Pfizer for its Matrix-M adjuvant, a deal seen by many as crucial validation for its non-mRNA technology. This development is intensifying community discussions about the stock's high short interest and potential for a squeeze, alongside ongoing pressure from an activist investor for management to expedite further partnerships and unlock core asset value.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is capturing significant attention following multiple analyst upgrades and reports of a substantial U.S. defense contract under the SHIELD program, fueling strong bullish sentiment. The community is actively discussing the stock's ability to maintain its upward momentum against price resistance ahead of its highly anticipated earnings report, with many expecting positive developments from its server CPU demand and foundry initiatives.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending due to heightened global market uncertainty, fueled by renewed tariff threats against European nations and the ongoing Greenland situation. The community is sharply divided, with some anticipating a familiar "buy the dip" opportunity for the tech-heavy index, while others fear a more sustained market correction if trade tensions further escalate.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as regulatory developments create a mixed outlook: a Massachusetts judge issued a preliminary injunction against prediction market Kalshi, a move seen as highly favorable for traditional sportsbooks. This positive catalyst is juxtaposed with the NCAA's call for a federal halt on college sports betting, intensifying investor debate around regulatory impacts and the rising competition from alternative betting platforms. Community sentiment is also weighing recent analyst upgrades and an increased share buyback authorization, leading to notable stock volatility.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is actively discussed following its announcement of a record date for a digital token initiative, with many anticipating a short squeeze and other upcoming catalysts. This drives significant polarization, as some investors see substantial upside from loyalist support, while others view it as a highly speculative, politically-charged stock susceptible to market volatility and dilution. The stock remains a key talking point, reflecting the strong intersection of media, branding, and political narratives in its trading dynamics.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is captivating attention following its selection for a critical Missile Defense Agency contract vehicle, sparking renewed bullish sentiment within the quantum computing sector. While bulls anticipate further momentum from upcoming industry events like CES, community discussions remain divided between those highlighting its technological advancements and others questioning its current valuation amidst ongoing R&D.

Top Wealth Group Holding Ltd. operates as a holding company, which provides caviar and caviar-based gourmet products. It focuses on supplying sturgeon caviar to customers under its own brand, Imperial Cristal Caviar. The company was founded by Kim Kwan Kings Wong on February 1, 2023 and is headquartered in Hong Kong.

Top Wealth Group Holding Ltd. - Ordinary Shares - Class A

Top Wealth Group Holding Ltd.

Top Wealth Group (TWG) is seeing significant conversation following its announced acquisition of a wine trading business valued at $125 million, to be paid in newly issued shares. This strategic expansion into luxury wine has ignited strong community debate, with investors split between concerns over the share dilution at $7.00 per share and those enthusiastically accumulating the stock on the belief of a future rebound. The intense volatility reflects the mixed sentiment surrounding this low-float entity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why SciSparc Stock Is Gaining Today

SciSparc shares are surging after it moved to acquire MUSE endoscopy IP, broadening beyond neuroscience into GERD device commercialization.read more...

<ul class="summary-bullets"><li>The company said it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device.</li><li>The number of shares issued to Xylo would be 19.99% of the issued and outstanding share capital of SciSparc as of the closing date of the transaction, SciSparc said.&nbsp;</li><li>Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion instead of issuing shares, it added.</li></ul> SciSparc Ltd. (SPRC) on Wednesday said that its majority-owned unit, NeuroThera Labs Inc., signed a binding term sheet to acquire a treasury of patents, trademarks, and intellectual property rights for innovative endoscopic systems and medical cameras from Xylo Technologies Ltd.Shares of the company jumped as much as 34% in the pre-market session at the time of writing.<h2 class="st-heading-2">About The Rights And Patents</h2>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/26/3195068/0/en/SciSparc-to-Acquire-Treasury-of-Patents-for-Innovative-Medical-Endoscopy-Systems.html">said</a> it is also acquiring intellectual property rights to the MUSE system, a single-use, innovative endoscopic device designed for a minimally invasive procedure to treat gastroesophageal reflux disease (GERD). According to SciSparc, the GERD device market is projected to reach $3.03 billion by 2030 from about $2.5 billion in 2024.In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. The number of shares issued would be 19.99% of SciSparc's issued and outstanding share capital as of the transaction's closing date, the company said.Scisparc may also issue pre-funded warrants to purchase ordinary shares at its discretion, rather than issuing shares. However, this is subject to negotiation and the signing of definitive acquisition agreements, the company added.<h2 class="st-heading-2">What Does SciSparc Intend To Do?</h2>Xylo had entered a licensing and distribution agreement with a Shanghai-based medical instruments company in 2019 for commercialization in Greater China.SciSparc now intends to replicate this model across territories such as North America, Europe and Latin America by pursuing exclusive partnerships with regional distributors to accelerate worldwide commercialization.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.SPRC stock is down by 68% this year and by about 49% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nyxoah-sa-stock-rises-pre-market-after-cms-raises-reimbursement-for-sleep-disorder-therapy/cL538b3REWB">Nyxoah SA Stock Rises Pre-Market After CMS Raises Reimbursement For Sleep Disorder Therapy</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

SciSparc Stock Soars Pre-Market After Snapping Up Patents For Next-Gen Endoscopy Tech

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 

Equity

In return, SciSparc shall issue to Xylo an amount of ordinary shares of the company. 


SciSparc (SPRC) announced on Monday that it has decided to terminate the proposed merger with AutoMax Motors.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/06/3161557/0/en/SciSparc-Ltd-Announces-Framework-Agreement-Regarding-Merger-with-AutoMax-Motors.html">announced</a> that the decision was mutual, and the merger agreement is null, effective immediately. The two companies also established clear repayment terms for SciSparc’s existing loans to AutoMax, totaling a principal amount of $6.25 million. The companies did not provide a reason for scrapping the proposed merger.SPRC shares traded 2% higher at the time of writing. Scisparc stated that AutoMax will repay $4.25 million in principal, with interest, in a single lump sum payment on Jan. 1, 2028, and another $2 million in principal, with interest, in monthly installments starting Nov. 20, 2025. All accrued interest will be paid at the outset, the company added.Late in August, the pharmaceutical company said that its shareholders approved its proposed merger with AutoMax, a parallel vehicle importer in Israel. The two companies entered into a definitive agreement in April 2024, under which SciSparc would acquire 100% of AutoMax’s share capital by way of a reverse merger between SciSparc Merger Sub, a wholly owned subsidiary of the company, and AutoMax, with AutoMax continuing as a wholly owned subsidiary of SciSparc. The proposed merger was aimed at diversifying SciSparc’s portfolio and capitalizing on the expanding electric vehicle market in Israel.SciSparc is currently focused on a portfolio based on cannabinoid pharmaceuticals. It is developing drugs for the treatment of Tourette Syndrome, Alzheimer’s disease, and Autistic Spectrum Disorders (ASD), among others.&nbsp;SPRC stock is down 37% this year but is up approximately 3% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

SciSparc And AutoMax Motors Scrap Proposed Merger

The decision was mutual, and the merger agreement is null, effective immediately, SciSparc said.

SciSparc’s (SPRC) shares soared over 61% on Thursday after the company announced its plans to launch an initiative to advance 3D protein modeling using quantum computing technology.SciSparc <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/25/3156166/0/en/SciSparc-Resolves-to-Launch-Innovative-Quantum-Computing-Enabled-3D-Protein-Modeling-Initiative-to-Revolutionize-AI-Drug-Discovery.html">will</a> form a dedicated research team to integrate quantum computing algorithms into 3D protein modeling to create new intellectual property. Initial efforts will focus on refining quantum algorithms to simulate protein dynamics and binding interactions, with the goal of targeting applications in drug discovery for neurological and rare diseases. SciSparc also said that it expects to incorporate a new wholly owned Israeli subsidiary, which will operate the initiative.The firm explained that knowing a protein’s three-dimensional structure is key to understanding how it interacts in the body and how to design effective drugs. Scientists typically use computers to predict the 3D structure. However, the process has its challenges, including the dynamic nature of proteins, which involves constantly shifting between different conformations, SciSparc said.Quantum computing may simulate the energy dynamics of proteins with greater precision, capturing their complex movements and interactions with potential drugs with much higher accuracy, the company said. The firm expressed optimism that this may pave the way for breakthroughs in structural biology and personalized medicine.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/SPRC">SPRC stock</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_25_at_12_19_35_PM_png_a67dccb366.webp" alt="SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits" width="576" height="64"><figcaption>SPRC's Sentiment Meter and Message Volume as of 12:19 p.m. ET on Sept. 25, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to hit $10 by the end of the day.<stembedurl>https://stocktwits.com/Proecadguy/message/629996574</stembedurl>Late last month, the company said that its shareholders approved its proposed merger with AutoMax Motors, a parallel vehicle importer in Israel. Following the closing of the merger, SciSparc shareholders are expected to hold approximately 50.01% of the combined company’s share capital. However, the merger's closing is subject to approval by the Israeli court.SPRC stock is down approximately 19% this year and up about 18% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/carmax-stock-tumbles-after-q2-earnings/chDlO6OR348">Why Did CarMax Stock Tumble 24% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

SciSparc Stock Soared 61% Today – Here’s An Important Update

The company will establish a dedicated research team to integrate quantum computing algorithms into 3D protein modeling, aiming to create new intellectual property.

SciSparc Ltd. is a clinical stage pharmaceutical company, which focuses on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. It operates through the Drug Development and Online Sales segments. The Drug Development segment focuses on cannabinoid molecules to be approved by an official regulatory authority. The Online Sales segment consists of hemp-based products including hemp gummies, hemp oil capsules, hemp gel, hemp cream, detox pills, height pills, antibacterial creams, and anti-aging creams, among other beauty and hair treatment products that are all manufactured in the United States. The company was founded on August 23, 2004 and is headquartered in Tel Aviv, Israel.

Current Price	$1.07
Prev Close	$1.07
Open	$1.05
Dividend Yield	0.00%
50-Day Moving Average	$1.88
Beta	0.87
Avg. Volume	1.21M
PE Ratio	-0.05

52-Week High	$14.91
52-Week Low	$0.9732
Market Capitalization	$4.66M
EPS (Annual)	-$22.65
Price to Book	-0.73
Revenue Per Employee	$653,000.00
Enterprise Value/EBITDA	N/A

SPRC
Scisparc Ltd

Feed

News

Sentiment

Fundamentals

Info

Latest SPRC News

SPRCScisparc Ltd